Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Breast Cancer

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.clbc.2014.10.006PMID 25441421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• 3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).

  2017cited by this paper
• GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer

  2013cited by this paper
• Global estimates of cancer prevalence for 27 sites in the adult population in 2008

  2013cited by this paper
• Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer.

  2013cited by this paper
• Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

  2013cited by this paper
• AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.

  2013cited by this paper
• Occurrence of breast cancer subtypes in adolescent and young adult women

  2012cited by this paper
• Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2012cited by this paper
• Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

  2012cited by this paper
• 1st International consensus guidelines for advanced breast cancer (ABC 1).

  2012cited by this paper
• CETUXIMAB COMBINED WITH INFUSIONAL 5-FLUOROURACIL/FOLINIC ACID AND OXALIPLATIN IN METASTATIC COLORECTAL CANCER: POOLED ANALYSIS OF COIN AND OPUS STUDY DATA

  2012cited by this paper
• E6. Can an international consensus meeting change the future of advanced breast cancer patients? Highlights from ABC1 Consensus Meeting

  2012cited by this paper
• Role of pertuzumab in the treatment of HER2-positive breast cancer.

  2012cited by this paper
• Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence

  2012cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer

  2012cited by this paper
• Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial.

  2012cited by this paper
• Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration

  2011cited by this paper
• Different mechanisms for resistance to trastuzumab versus lapatinib in HER2- positive breast cancers -- role of estrogen receptor and HER2 reactivation

  2011cited by this paper
• The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.

  2011cited by this paper
• RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.

  2011cited by this paper
• Trastuzumab Emtansine: A Unique Antibody-Drug Conjugate in Development for Human Epidermal Growth Factor Receptor 2–Positive Cancer

  2011cited by this paper
• The role of chemotherapy and targeted agents in patients with metastatic breast cancer.

  2011cited by this paper
• Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much?

  2010cited by this paper
• Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2010cited by this paper
• Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer

  2010cited by this paper
• Breast cancer subtypes and the risk of local and regional relapse.

  2010cited by this paper
• Lapatinib – Member of a New Generation of ErbB-Targeting Drugs

  2010cited by this paper
• Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

  2010cited by this paper
• Everolimus

  2010cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

  2009cited by this paper
• Mechanism of action of everolimus in renal cell carcinoma

  2009cited by this paper
• Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.

  2009cited by this paper
• Non-communicable diseases must have greater priority, says WHO

  2009cited by this paper
• Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study.

  2009cited by this paper
• Her2-positive breast cancer: herceptin and beyond.

  2008cited by this paper
• The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2

  2008cited by this paper
• Enabling personalized cancer medicine through analysis of gene-expression patterns

  2008cited by this paper
• Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.

  2008cited by this paper
• The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

  2007cited by this paper
• Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer.

  2007cited by this paper
• Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer

  2007cited by this paper
• Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer.

  2006cited by this paper
• Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

  2005cited by this paper
• Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.

  2005cited by this paper
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs

  2005cited by this paper
• Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas.

  2005cited by this paper
• The role of growth factor receptor pathways in human breast cancer cells adapted to long-term estrogen deprivation.

  2005cited by this paper
• Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

  2004cited by this paper
• Pathology and Genetics of Tumours of the Breast and Female Genital Organs

  2003cited by this paper
• World Health Organization Classification of Tumours

  2002cited by this paper
• AJCC Cancer Staging Manual

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Assessing the quality of reports of randomized clinical trials: is blinding necessary?

  1996cited by this paper
• Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

  1987cited by this paper
• The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

  1984cited by this paper

• Efficacy and safety of first‐line regimens for advanced HER2‐positive breast cancer: A Bayesian network meta‐analysis

  2024cites this paper
• Immune and molecular landscape behind non-response to Mycophenolate Mofetil and Azathioprine in lupus nephritis therapy

  2024cites this paper
• Optimizing treatment for HER2-positive HR-positive breast cancer.

  2023cites this paper
• Conventional and Advanced Therapeutic Approaches in Breast Cancer Treatment

  2023cites this paper
• Breast Cancer Associated Conventional and Advanced Therapies 

  2023cites this paper
• Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines

  2023cites this paper
• Comparative review of pharmacological therapies in individuals with HER2-positive advanced breast cancer with focus on hormone receptor subgroups

  2022cites this paper
• Rituximab versus tocilizumab in rheumatoid arthritis: synovial biopsy-based biomarker analysis of the phase 4 R4RA randomized trial

  2022cites this paper
• Anti-proliferative and anti-migratory effects of EGFR and c-Met tyrosine kinase inhibitors in triple negative breast cancer cells

  2021cites this paper
• The genomic architecture of metastasis in breast cancer: focus on mechanistic aspects, signalling pathways and therapeutic strategies

  2021cites this paper
• rGO nanomaterial-mediated cancer targeting and photothermal therapy in a microfluidic co-culture platform

  2020cites this paper
• Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

  2019cites this paper
• Research progress of Axl inhibitors.

  2019cites this paper
• Overview of Current Immunotherapies Targeting Mutated KRAS Cancers.

  2019cites this paper
• Effectiveness and safety of a robot-assisted 3D personalized template in 125I seed brachytherapy of thoracoabdominal tumors

  2018cites this paper
• ADSCs and adipocytes are the main producers in the autotaxin–lysophosphatidic acid axis of breast cancer and healthy mammary tissue in vitro

  2018cites this paper
• Efficacy and safety of a combination of HER2-targeted agents as first-line treatment for metastatic HER2-positive breast cancer: a network meta-analysis

  2018cites this paper
• The clinical benefit of epidermal growth factor receptor and human epidermal growth factor receptor 2 targeted agents adding to endocrine therapy in hormone receptor-positive breast cancer

  2018cites this paper
• Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer

  2018cites this paper
• Use and outcomes of targeted therapies in early and metastatic HER2-positive breast cancer in Australia: protocol detailing observations in a whole of population cohort

  2017cites this paper
• University of Groningen Health technology assessment of imaging technologies for breast cancer screening and follow-up Koleva-Kolarova,

  2017cites this paper
• Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials

  2017cites this paper
• Targeted therapies in breast cancer: New challenges to fight against resistance

  2017cites this paper
• USP43 promotes tumorigenesis through regulating cell cycle and EMT in breast cancer.

  2017cites this paper
• Chapter 11 – Lapatinib

  2017cites this paper
• Effects of Z-venusol, isolated from Gunnera perpensa L., on IL-6 and cAMP activity in human breast cancer cells in vitro

  2017cites this paper
• Increased life expectancy as a result of non-hormonal targeted therapies for HER 2 or 1 hormone receptor positive metastatic breast cancer : a systematic review and meta-2 analysis 3 4

  2017influential citation
• Increased life expectancy as a result of non-hormonal targeted therapies for HER2 or hormone receptor positive metastatic breast cancer: A systematic review and meta-analysis.

  2017cites this paper
• Nanotechnology for the delivery of phytochemicals in cancer therapy.

  2016cites this paper
• Folic acid functionalized long-circulating co-encapsulated docetaxel and curcumin solid lipid nanoparticles: In vitro evaluation, pharmacokinetic and biodistribution in rats

  2016cites this paper
• Sonographic Detection of Metastatic Breast Cancer in the Liver

  2016cites this paper
• JWA loss promotes cell migration and cytoskeletal rearrangement by affecting HER2 expression and identifies a high-risk subgroup of HER2-positive gastric carcinoma patients

  2016cites this paper
• The Efficacy of Trastuzumab in Animal Models of Breast Cancer: A Systematic Review and Meta-Analysis

  2016cites this paper
• Chapter 3 – Enzymatic Biosensors

  2015cites this paper
• Drug and gene delivery across the blood-brain barrier with focused ultrasound.

  2015cites this paper
• Proteomic approach to understand metastatic spread

  2015cites this paper
• Discovery of New Acid Ceramidase-Targeted Acyclic 5-Alkynyl and 5-Heteroaryl Uracil Nucleosides.

  2015cites this paper
• Tumor‐induced inflammation in mammary adipose tissue stimulates a vicious cycle of autotaxin expression and breast cancer progression

  2015cites this paper
• Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

  2015cites this paper
• Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome

  2015cites this paper